Celgene 3rd quarter profit up 37 percent; edges above forecast
October 23, 2014 at 07:46 AM EDT
Oct 23 (Reuters) - Celgene Corp on Thursday reported third quarter profit rose 37 percent on increased sales of its flagship multiple myeloma medicine Revlimid and strong demand for its other drugs, and the U.S. biotechnology company raised its full-year earnings forecast.
